JP2017517520A5 - - Google Patents

Download PDF

Info

Publication number
JP2017517520A5
JP2017517520A5 JP2016569847A JP2016569847A JP2017517520A5 JP 2017517520 A5 JP2017517520 A5 JP 2017517520A5 JP 2016569847 A JP2016569847 A JP 2016569847A JP 2016569847 A JP2016569847 A JP 2016569847A JP 2017517520 A5 JP2017517520 A5 JP 2017517520A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
composition according
patient
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016569847A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017517520A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/032351 external-priority patent/WO2015183776A1/en
Publication of JP2017517520A publication Critical patent/JP2017517520A/ja
Publication of JP2017517520A5 publication Critical patent/JP2017517520A5/ja
Pending legal-status Critical Current

Links

JP2016569847A 2014-05-29 2015-05-26 Ｗｅｅ１阻害剤を用いた癌を処置する方法 Pending JP2017517520A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004298P 2014-05-29 2014-05-29
US62/004,298 2014-05-29
PCT/US2015/032351 WO2015183776A1 (en) 2014-05-29 2015-05-26 Methods for treating cancer with a wee1 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019232432A Division JP2020073520A (ja) 2014-05-29 2019-12-24 Ｗｅｅ１阻害剤を用いた癌を処置する方法

Publications (2)

Publication Number Publication Date
JP2017517520A JP2017517520A (ja) 2017-06-29
JP2017517520A5 true JP2017517520A5 (enExample) 2018-06-28

Family

ID=54699632

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016569847A Pending JP2017517520A (ja) 2014-05-29 2015-05-26 Ｗｅｅ１阻害剤を用いた癌を処置する方法
JP2019232432A Pending JP2020073520A (ja) 2014-05-29 2019-12-24 Ｗｅｅ１阻害剤を用いた癌を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019232432A Pending JP2020073520A (ja) 2014-05-29 2019-12-24 Ｗｅｅ１阻害剤を用いた癌を処置する方法

Country Status (4)

Country Link
US (3) US20170095479A1 (enExample)
EP (1) EP3148544A4 (enExample)
JP (2) JP2017517520A (enExample)
WO (1) WO2015183776A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017517520A (ja) * 2014-05-29 2017-06-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｗｅｅ１阻害剤を用いた癌を処置する方法
WO2019134070A1 (en) * 2018-01-02 2019-07-11 Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine Panda as novel therapeutic
MA54543A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
AU2020407070A1 (en) * 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations
MX2022012992A (es) * 2020-04-14 2022-11-08 Amgen Inc Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas.
CA3180664A1 (en) * 2020-06-17 2021-12-23 Yuli Xie Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor
CA3183025A1 (en) * 2020-06-24 2021-12-30 Melissa Dumble Companion diagnostic tool for mutant p53 reactivating compounds
IL310863A (en) 2021-08-26 2024-04-01 Volastra Therapeutics Inc Spiro indoline inhibitors of kif18a
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5129812B2 (ja) * 2007-06-15 2013-01-30 Ｍｓｄ株式会社 ビシクロアニリン誘導体
US20120157342A1 (en) * 2009-09-02 2012-06-21 Shinji Mizuarai Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
RU2017127088A (ru) * 2010-11-16 2019-02-04 Эррэй Биофарма Инк. Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1
US9506926B2 (en) * 2011-02-18 2016-11-29 The Regents Of The University Of California Molecular predictors of therapeutic response to specific anti-cancer agents
WO2013039854A1 (en) * 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
JP2017517520A (ja) * 2014-05-29 2017-06-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｗｅｅ１阻害剤を用いた癌を処置する方法

Similar Documents

Publication Publication Date Title
JP2017517520A5 (enExample)
JP2021521194A5 (enExample)
JP2016525097A5 (enExample)
PE20170312A1 (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso
JP2015533176A5 (enExample)
MX2021001583A (es) Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso.
JP2018507249A5 (enExample)
NZ602385A (en) Methods of treating cancer
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX2018005071A (es) Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp.
JO3556B1 (ar) علاجات مدمجة لمعالجة السرطان
MX2015011752A (es) Metodos para tratar cancer de pulmon.
PH12015502046B1 (en) Pyridinyl and fused pyridinyl triazolone derivatives
PH12016502354A1 (en) Pharmaceutical composition
MX2017015936A (es) Nueva composicion farmaceutica que comprende agentes tensioactivos no ionicos.
MX2018004328A (es) Composiciones farmaceuticas estabilizantes de camptotecina.
MX2020004476A (es) Compuestos piridinicos de pladienolida y metodos de uso.
JP2017528475A5 (enExample)
JP2017527582A5 (enExample)
GB2538683A8 (en) Irinotecan hydrochloride composite phospholipid composition preparation method and use thereof
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
JP2015502926A5 (enExample)
WO2016127168A3 (en) Mebendazole polymorph for treatment and prevention of tumors